Kareem N Rayn1, Graham R Hale1, Jonathan B Bloom1, Samuel A Gold1, Filipe L F Carvalho2, Sherif Mehralivand1, Marcin Czarniecki3, Bradford J Wood4, Maria J Merino5, Peter Choyke6, Barış Türkbey3, Peter A Pinto1, Piyush K Agarwal1. 1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 2. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Urology MedStar Georgetown University Hospital, Washington, DC, USA. 3. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 4. Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 5. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 6. Molecular Imaging Program National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE: In the era of multiparametric magnetic resonance imaging (mpMRI) of the prostate gland, incidental findings are occasionally discovered on imaging. We aimed to report our experience of detecting incidental bladder cancers on mpMRI of the prostate in asymptomatic patients without irritative voiding symptoms or microscopic or gross hematuria. METHODS: A retrospective review was performed on a prospectively maintained database of all men who underwent prostate mpMRI at our institution from 2012 to 2018. Patients who were found to have incidental bladder lesions were identified and baseline demographics, imaging and histopathologic data were recorded. All patients with incidental bladder lesion detection on mpMRI, not attributable to extension of prostate cancer, underwent cystoscopy in addition to a biopsy and/or transurethral resection of bladder tumor (TURBT) if warranted on cystoscopy. RESULTS: There were 3147 prostate mpMRIs performed during this period and 25 cases (0.8%) of incidental bladder lesions were detected. These patients did not have any presenting symptoms such as gross or microscopic hematuria to prompt bladder lesion workup. The largest diameter of incidentally discovered bladder lesions ranged from 0.4 cm to 1.7 cm. Of the 25 cases of incidental bladder lesions, five were suspected to be due to prostate cancer invasion into the bladder. Only two of these five patients underwent biopsy, which confirmed prostate adenocarcinoma in both cases. Of the 20 patients without suspected prostate cancer invasion of the bladder, four had no suspicious lesions on cystoscopy to warrant a biopsy. The remaining 16 patients had bladder lesions seen on cystoscopy and underwent a biopsy and/or TURBT. Three of these patients had benign features on pathology (urachal remnant, amyloidosis and inflammation) and the remaining 13 had stage Ta urothelial carcinoma. Seven of these patients had low-grade Ta tumors and six had high-grade Ta tumors. All patients were treated with standard management of TURBT with or without intravesical BCG. There have been no reported cases of recurrence or progression in any of the patients in our cohort at the median follow-up of 26 months (interquartile range,19-40 months). CONCLUSION: mpMRI of the prostate may yield incidental findings, such as small bladder tumors. Awareness of the possibility of incidental bladder lesions is important as 65% of lesions reported in the bladder, not attributable to extension of prostate cancer, proved to be bladder cancer. This may allow for early intervention for asymptomatic patients with undetected bladder cancer prior to disease progression.
PURPOSE: In the era of multiparametric magnetic resonance imaging (mpMRI) of the prostate gland, incidental findings are occasionally discovered on imaging. We aimed to report our experience of detecting incidental bladder cancers on mpMRI of the prostate in asymptomatic patients without irritative voiding symptoms or microscopic or gross hematuria. METHODS: A retrospective review was performed on a prospectively maintained database of all men who underwent prostate mpMRI at our institution from 2012 to 2018. Patients who were found to have incidental bladder lesions were identified and baseline demographics, imaging and histopathologic data were recorded. All patients with incidental bladder lesion detection on mpMRI, not attributable to extension of prostate cancer, underwent cystoscopy in addition to a biopsy and/or transurethral resection of bladder tumor (TURBT) if warranted on cystoscopy. RESULTS: There were 3147 prostate mpMRIs performed during this period and 25 cases (0.8%) of incidental bladder lesions were detected. These patients did not have any presenting symptoms such as gross or microscopic hematuria to prompt bladder lesion workup. The largest diameter of incidentally discovered bladder lesions ranged from 0.4 cm to 1.7 cm. Of the 25 cases of incidental bladder lesions, five were suspected to be due to prostate cancer invasion into the bladder. Only two of these five patients underwent biopsy, which confirmed prostate adenocarcinoma in both cases. Of the 20 patients without suspected prostate cancer invasion of the bladder, four had no suspicious lesions on cystoscopy to warrant a biopsy. The remaining 16 patients had bladder lesions seen on cystoscopy and underwent a biopsy and/or TURBT. Three of these patients had benign features on pathology (urachal remnant, amyloidosis and inflammation) and the remaining 13 had stage Ta urothelial carcinoma. Seven of these patients had low-grade Ta tumors and six had high-grade Ta tumors. All patients were treated with standard management of TURBT with or without intravesical BCG. There have been no reported cases of recurrence or progression in any of the patients in our cohort at the median follow-up of 26 months (interquartile range,19-40 months). CONCLUSION: mpMRI of the prostate may yield incidental findings, such as small bladder tumors. Awareness of the possibility of incidental bladder lesions is important as 65% of lesions reported in the bladder, not attributable to extension of prostate cancer, proved to be bladder cancer. This may allow for early intervention for asymptomatic patients with undetected bladder cancer prior to disease progression.
Authors: M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer Journal: J Urol Date: 2007-12 Impact factor: 7.450
Authors: Dengfeng Cao; Robin T Vollmer; Jason Luly; Samay Jain; Timur M Roytman; Charles W Ferris; M'liss Ann Hudson Journal: Urology Date: 2010-04-08 Impact factor: 2.649
Authors: Daniel Ramirez; Amit Gupta; Daniel Canter; Brian Harrow; Ryan W Dobbs; Victor Kucherov; Edward Mueller; Necole Streeper; Matthew A Uhlman; Robert S Svatek; Edward M Messing; Yair Lotan Journal: BJU Int Date: 2015-10-29 Impact factor: 5.588
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Al Sardari; John V Thomas; Jeffrey W Nix; Jason A Pietryga; Rupan Sanyal; Jennifer B Gordetsky; Soroush Rais-Bahrami Journal: Case Rep Urol Date: 2015-12-13
Authors: Elizabeth A Shephard; Sally Stapley; Richard D Neal; Peter Rose; Fiona M Walter; William T Hamilton Journal: Br J Gen Pract Date: 2012-09 Impact factor: 5.386
Authors: Giuseppe Cutaia; Gaetano Tosto; Roberto Cannella; Alberto Bruno; Claudio Leto; Leonardo Salvaggio; Sofia Cutaia; Francesco Paolo Lombardo; Nino Dispensa; Dario Giambelluca; Massimo Midiri; Giuseppe Salvaggio Journal: Radiol Med Date: 2019-11-29 Impact factor: 3.469